Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: J Thorac Oncol. 2020 Dec 8;16(3):419–427. doi: 10.1016/j.jtho.2020.11.021

Figure 2. Validation of the predictive value of the compound mutation signature in an independent cohort of ICB-treated NSCLC patients.

Figure 2.

Kaplan-Meier survival curve of 156 ICB-treated NSCLC patients with wt, single, or compound mutation signatures. HR (Compound vs wt): 0.42 (95% [CI]: 0.24–0.71). P values calculated by use of logrank test.